Eliza PS Tsou, PhD

Eliza Tsou
Frederick G L Huetwell Research Professor of Rheumatology II
Assistant Professor of Internal Medicine
Assistant Professor of Pharmacology
Medical School
Michigan Medicine
Internal Medicine/Rheumatology
2800 Plymouth Road, Building 20, Room 1822
Ann Arbor, Michigan 48109
[email protected]
Available to mentor
Eliza PS Tsou, PhD
Eliza Tsou
Assistant Professor
  • Qualifications
  • Center Memberships
  • Recent Publications
  • Manage Your Profile

  • Qualifications

    • PhD, Department of Pharmaceutical Sciences. School of Pharmacy
      University at Buffalo, State University of New York, Buffalo, NY, United States
      2002 - 2008
    • BSc, Department of Pharmacy
      National Taiwan University, Taipei, Taiwan
      1997 - 2001

    Center Memberships

    • Center Member
      Samuel and Jean Frankel Cardiovascular Center
    • Center Member
      Global REACH

    Recent Publications

    See All Publications
    • Journal Article
      Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis
      Ma F, Tsou PS, Gharaee-Kermani M, Plazyo O, Xing X, Kirma J, Wasikowski R, Hile GA, Harms PW, Jiang Y, Xing E, Nakamura M, Ochocki D, Brodie WD, Pillai S, Maverakis E, Pellegrini M, Modlin RL, Varga J, Tsoi LC, Lafyatis R, Kahlenberg JM, Billi AC, Khanna D, Gudjonsson JE. Nature Communications, 2024 Dec 1; 15 (1): DOI:10.1038/s41467-023-44645-6
      PMID: 38172207
    • Journal Article
      Single-cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa
      van Straalen KR, Ma F, Tsou PS, Plazyo O, Gharaee-Kermani M, Calbet M, Xing X, Sarkar MK, Uppala R, Harms PW, Wasikowski R, Nahlawi L, Nakamura M, Eshaq M, Wang C, Dobry C, Kozlow JH, Cherry-Bukowiec J, Brodie WD, Wolk K, Uluçkan Ö, Mattichak MN, Pellegrini M, Modlin RL, Maverakis E, Sabat R, Kahlenberg JM, Billi AC, Tsoi LC, Gudjonsson JE. Journal of Clinical Investigation, 2024 Feb 10; 134 (3): DOI:10.1172/JCI169225
      PMID: 38051587
    • Journal Article
      Senescent Cells Accumulate in Systemic Sclerosis Skin
      Shi B, Tsou PS, Ma F, Mariani MP, Mattichak MN, LeBrasseur NK, Chini EN, Lafyatis R, Khanna D, Whitfield ML, Gudjonsson JE, Varga J. Journal of Investigative Dermatology, 2023 Apr 1; 143 (4): 661 - 664.e5. DOI:10.1016/j.jid.2022.09.652
      PMID: 36191640
    • Journal Article
      Endothelial cell-derived plasminogen activator inhibitor-1 potentiates thrombosis in antiphospholipid syndrome.
      Gan Y, Liang W, Liu C, Yalavarthi S, Warnock M, Sabb K, Sarosh C, Schaefer JK, Tambralli A, Madison JA, Emal CD, Tsou P-S, Shi H, Zuo Y, Lawrence DA, Knight JS. J Autoimmun, 2026 Apr 27; 161: 103563 DOI:10.1016/j.jaut.2026.103563
      PMID: 42048835
    • Journal Article
      Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.
      Nunez D, Volkov JR, Little C, Ghosh M, Tsou P-S, Furmanak T, Dey P, Tsoi LC, Zahn C, Bogle R, Cai Y, Fox J, Stadanlick J, Werner M, Vorndran Z, Ishikawa L, Ellis A, Williams J, Cicarelli J, Flannagan S, Kobulsky D, Lam Q, Schmitt C, Nezhad F, Thompson D, Braccia D, Rivera TG, Tummala R, Gudjonsson JE, Ross C, Binder G, Chang D, Basu S, Khanna D. Mol Ther Adv, 2026 Mar 12; 34 (1): 201663 DOI:10.1016/j.omta.2025.201663
      PMID: PMC13182784
    • Journal Article
      Nintedanib Attenuates Profibrotic Gene Expression in a 3D Organotypic Culture Model of Systemic Sclerosis Skin Fibrosis.
      Shah K, Verma P, Hamil T, Dey P, Bale S, Yalavarthi B, Tsou P-S, Gudjonsson JE, Khanna D, Varga J, Bhattacharyya S. J Invest Dermatol, 2026 Mar 6; DOI:10.1016/j.jid.2026.01.046
      PMID: 41796853
    • Proceeding / Abstract / Poster
      Endothelial cell mediators reflecting angiopoietin and interferon pathway activation characterize juvenile dermatomyositis disease activity and autoantibody subgroups
      Grant K, Matossian S, Rosek A, Sturza J, Chen L, Madubata C, Barnett D, Neely J, Torok K, Kahlenberg JM, Tsou E, Turnier J. 2026 Mar 24;
    • Journal Article
      Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.
      Kaundal U, Tsou P-S, Sahu M, Huang M, Boyden SE, Woodford CM, Shriner D, Stenson E, Safran SA, Zhou Y, Talley TA, Gudapati K, Zhang X, Kunishita Y, Wang J, Shah AA, Mayes MD, Doumatey AP, Bentley AR, Domsic R, Medsger TA, Ramos PS, Silver RM, Steen V, Varga J, Hsu V, Saketkoo LA, Schiopu E, Gordon JK, Criswell LA, Gladue H, Derk C, Bernstein EJ, Bridges SL, Shanmugam V, Chung L, Kafaja S, Jan R, Trojanowski M, Goldberg A, Korman BD, Mullikin J, Thomas JW, Dell'Orso S, Randazzo D, Adeyemo A, Remmers EF, Schwartzberg PL, Aksentijevich I, Rotimi C, Wigley FM, Wang RA, Boin F, Khanna D, Lafyatis R, Kastner DL, Gourh P. Ann Rheum Dis, 2026 Feb 4; DOI:10.1016/j.ard.2025.12.015
      PMID: 41644364

    Featured News & Stories

    lungs beating pink and orange and yellow and white circles floating around
    Health Lab

    Protein found in rheumatic diseases causes inflammation in COVID-19 patients

    Research on the inflammatory mediator called sCD13 has identified this molecule and its receptors as new targets for treatment of autoimmune rheumatic diseases. The data suggests that sCD13 may also be of great importance in severe complications of COVID-19.
    microscope
    Health Lab

    Targeting and blocking sCD13 protein could lead to systemic sclerosis treatment

    Targeting and blocking the sCD13 protein from interacting with the B1R protein can pave the way for new fibrosis and systemic sclerosis treatments.